Streetbeat News

Analyst Ratings

EDSA

HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Edesa Biotech (NASDAQ:EDSA), maintaining a $21 price target. This reaffirmation of confidence in Edesa Biotech suggests a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 11:27 am

OCUL

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Ocular Therapeutix (NASDAQ:OCUL) and maintained a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 11:25 am

RZLT

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Rezolute (NASDAQ:RZLT) and maintained a $14 price target.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 11:20 am

TWLO

HSBC analyst Stephen Bersey downgrades Twilio (NYSE:TWLO) from Hold to Reduce and sets a new price target of $61.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 11:16 am

CBAY

Piper Sandler analyst Yasmeen Rahimi downgraded CymaBay Therapeutics (CBAY) from Overweight to Neutral and reduced the price target from $33 to $32.5.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 11:11 am

C

Piper Sandler analyst Scott Siefers upgrades Citigroup (NYSE:C) from Neutral to Overweight and raises the price target from $56 to $63.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 11:09 am

HPQ

HSBC analyst Stephen Bersey upgrades HP (NYSE:HPQ) from Hold to Buy and raises the price target from $30 to $33, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 11:08 am

AMD

NVDA

Nvidia Corp. (NVDA) faces potential concerns despite its significant rise in 2023, with UBS analyst Timothy Arcuri noting a decrease in lead times for Nvidia's chips, suggesting potential for increased shipments and revenue. However, short seller Jim Chanos and others view this as a negative sign, indicating possible waning demand. The situation is complicated by Nvidia's strong position in the AI market, competition, and reliance on key markets like Singapore. Nvidia's upcoming quarterly earnings report on Feb. 21 may provide further insights.

Portfolio Pulse from Shanthi Rexaline

February 14, 2024 | 11:03 am

BRKR

JP Morgan analyst Tycho Peterson upgraded Bruker (NASDAQ:BRKR) from Neutral to Overweight and increased the price target from $60 to $90.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 10:59 am

BIIB

Needham analyst Ami Fadia maintains a Buy rating on Biogen (NASDAQ:BIIB) but lowers the price target from $305 to $300.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 10:56 am